Evidence map›Paper›PMID 31144145›Full record

Trial reportInternational journal of clinical oncology2019

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).

Nobuaki Suzuki, Shoichi Hazama, Takeshi Nagasaka, Hiroaki Tanioka, Yasuo Iwamoto, Yuji Negoro, Masami Yamauchi, Michiya Kobayashi, Hiroshi Okuda, Noriaki Fujishima and 8 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.International journal of clinical oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

Nobuaki SuzukiDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan. nobusuzu@yamaguchi-u.ac.jp.ORCID http://orcid.org/0000-0001-8391-2395
Shoichi HazamaDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Takeshi NagasakaDepartment of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan.
Hiroaki TaniokaDepartment of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan.
Yasuo IwamotoDepartment of Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Yuji NegoroDepartment of Medical Oncology, Kochi Health Sciences Center, Kochi, Japan.
Masami YamauchiDivision of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Michiya KobayashiCancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan.
Hiroshi OkudaSurgery and Endoscopic Surgery, Onomichi General Hospital, Onomichi, Japan.
Noriaki FujishimaDepartment of Surgery, Fukuda Clinic of Internal Medicine, Heart and Digestive, Kochi, Japan.
Taku NishimuraDepartment of Surgery, Kokura Memorial Hospital, Kokura, Japan.
Naoki YamanakaDepartment of Surgery, Japanese Red Cross Yamaguchi Hospital, Yamaguchi, Japan.
Kazuhiro ToyotaDepartment of Surgery, National Hospital Organization Higashihiroshima Medical Center, Hiroshima, Japan.
Yoshiko MoriDepartment of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yuki NakagamiDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Mototsugu ShimokawaCancer Biostatistics Laboratory, Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.
Hiroaki NaganoDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Masazumi OkajimaDepartment of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Yamaguchi University · JPHiroshima City Asa Citizens Hospital · JPKawasaki Medical School · JPKochi Medical School Hospital · JPFukuda Denshi (Japan) · JPHigashihiroshima Medical Center · JPHiroshima Prefectural Hospital · JPKokura Memorial Hospital · JPNational Hospital Organization Kyushu Cancer Center · JPOkayama University · JPOnomichi General Hospital · JPYamaguchi Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Recently, it has reported that mCAPIRI is well tolerated and non-inferior to FOLFIRI. In this study, we conducted a multicenter phase II trial to assess the efficacy and safety of biweekly CAPIRI plus bevacizumab as second-line chemotherapy for mCRC with reduced toxicity and preserved efficacy.

methodsPatients with mCRC who had received prior chemotherapy, including oxaliplatin-based regimens, were eligible for this study. The treatment protocol administered capecitabine at 1000 mg/m

resultsFifty-one patients were enrolled in this study. Median PFS was 5.5 months [95% confidence interval (CI) 4.23-7.40 months], and median OS was 13.5 months (95% CI 11.57-20.23 months). The RR was 14.6% (95% CI 6.5-28.4%), and the DCR was 66.7% (95% CI 51.5-79.2%). Hypertension was the most common Grade 3 adverse event (27.5%), followed by neutropenia (17.6%). Only two patients suffered from grade 3 hand-foot syndrome.

conclusionsIn mCRC patients, biweekly CAPIRI + bevacizumab appears effective and feasible as a second-line chemotherapy with relatively low toxicities, and has potential as a useful substitute for FOLFIRI + bevacizumab.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCapecitabineColorectal NeoplasmsFemaleHumansIrinotecanMaleMiddle AgedNeoplasm MetastasisPrognosisSurvival RateBevacizumabCapecitabineIrinotecanBevacizumabBiweeklyCAPIRImCRCSecond line

Identifiers

PMID31144145
PMCPMC6736909
OpenAlexW2947024158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.